Cross-category comparison
ESG vs Wegovy Tablets
Different categories, normalised only where comparison is meaningful.
Endoscopic sleeve gastroplasty
Less average weight loss than sleeve/bypass but more substantial than lifestyle alone for selected patients; evidence base is growing
Wegovy tablets
OASIS 4: mean -13.6% at 64 weeks under treatment-policy analysis; -16.6% estimated while on treatment without additional obesity therapy
How to use this comparison
Compare the factual differences below. We do not assign numerical treatment rankings: outcomes depend on the specific treatment, population, follow-up and your clinical circumstances.
Category-specific detail
| Issue | Endoscopic sleeve gastroplasty | Wegovy tablets |
|---|---|---|
| Anatomical change | Internal endoscopic sutures reduce stomach volume without removing stomach tissue | Not covered in this row |
| Diabetes / metabolic | Metabolic benefit through weight loss; less evidence depth than bypass surgery | Not covered in this row |
| Evidence anchor | Not covered in this row | OASIS 4: mean -13.6% at 64 weeks under treatment-policy analysis; -16.6% estimated while on treatment without additional obesity therapy |
| How it works | Not covered in this row | GLP-1 receptor agonist |
| How taken | Not covered in this row | Daily tablet — Once daily |
| Main trade-offs | Not covered in this row | Daily dosing; Administration instructions and adherence matter; Newer UK formulation with less real-world maturity; NICE/NHS reimbursement position may differ from injectable Wegovy |
| Maintenance | Not covered in this row | Long-term treatment / maintenance planning still applies |
| NHS context | NHS now describes ESG as a weight-loss procedure, but availability is not universal | Licensed; NICE/NHS positioning may lag the new formulation and should be checked live |
| Nutrition burden | Lower malabsorptive burden because intestine is not bypassed | Not covered in this row |
| Procedure type | Endoscopic suturing procedure | Not covered in this row |
| Reflux | May be preferable to sleeve in some reflux contexts, but individual assessment matters | Not covered in this row |
| Reversible | Potentially revisable/reversible in some circumstances, but not equivalent to simply 'undoing' a band | Not covered in this row |
| Revision | Can be followed by surgical bariatric procedures in selected cases | Not covered in this row |
| UK licence | Not covered in this row | UK weight management licence |
A detail omitted from one column is not evidence that it is irrelevant to that treatment. Use the full guides and discuss clinical suitability with your treating team.
Want support putting this into practice?
The Shift Programme is being built to combine evidence-led education, decision support, practical tools, progress tracking and long-term maintenance.
Sources & evidence
Check the underlying guidance directly: